Free Alerts   Login
Health Care › Pharmaceutical Preparations

JAZZ Stock Price Correlated With Jazz Pharmaceuticals Financials

JAZZ Stock Price vs. Quarterly
JAZZ
Income Statement
Cash Flow
Balance Sheet

JAZZ Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

JAZZ Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

JAZZ Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Johnson Philip L   EVP & Chief Financial Officer
27,932 sh at $51
$1,435,800
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
7,056,032 sh
-130,845 sh
-2%
$867,893
-$62,375
Vanguard Group
6,363,748 sh
-15,305 sh
0%
$782,741
-$42,963
State Street
2,421,125 sh
96,077 sh
4%
$297,798
-$3,156
Lsv Asset Management
2,343,227 sh
-28,950 sh
-1%
$288
-$19
JPMorgan Chase
1,397,284 sh
-28,757 sh
-2%
$171,866
-$12,723
Ameriprise Financial
1,312,771 sh
13,159 sh
1%
$161,471
-$6,751
Wellington Management Group Llp
1,280,197 sh
-388,314 sh
-23%
$157,464
-$58,508
Polaris Capital Management
1,267,460 sh
27,100 sh
2%
$155,898
-$4,654
Renaissance Technologies
1,231,574 sh
-76,041 sh
-6%
$151
-$18
FMR
1,228,991 sh
-104,138 sh
-8%
$151,165
-$21,395
Geode Capital Management
1,049,388 sh
36,641 sh
4%
$128,875
-$2,063
Pacer Advisors.
1,023,706 sh
224,865 sh
28%
$125,916
$22,514
Ecor1 Capital
1,013,952 sh
645,541 sh
175%
$124,716
$79,044
Franklin Resources
877,509 sh
-157,114 sh
-15%
$107,934
-$25,988
Baupost Group
833,696 sh
160,000 sh
24%
$102,545
$15,342
Morgan Stanley
778,803 sh
-37,014 sh
-5%
$95,793
-$9,806
Dimensional Fund Advisors
765,846 sh
-29,766 sh
-4%
$94,200
-$8,788
Bnp Paribas Asset Management Holding S.A.
712,811 sh
-50,275 sh
-7%
$87
-$12
Camber Capital Management Lp
675,000 sh
675,000 sh
NEW
$83,025
$83,025
Armistice Capital
651,626 sh
195,626 sh
43%
$80,150
$23,620
COMPANY PROFILE
Organization and Description of Business Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases - often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we strive to identify new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Our lead marketed products are:

Neuroscience

• Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution , a product approved by the U.S. Food and Drug Administration, or FDA, in July 2020 and launched in the U.S. in November 2020 for the treatment of cataplexy or excessive daytime sleepiness, or EDS, in patients with narcolepsy aged seven years of age and older, and also approved by FDA in August 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in November 2021. Xywav contains 92% less sodium than Xyrem®;

• Xyrem (sodium oxybate) oral solution , a product approved by FDA and distributed in the U.S. for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Jazz also markets Xyrem in Canada for the treatment of cataplexy in patients with narcolepsy. Xyrem is also approved and distributed in Europe, Great Britain and other markets through a licensing agreement;

• Epidiolex® (cannabidiol) oral solution , a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older; in Europe (where it is marketed as Epidyolex®) and other markets, it is approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures associated with tuberous sclerosis complex in patients 2 years of age and older;

• Sunosi® (solriamfetol) , a product approved by FDA and marketed in the U.S., Canada, Europe and Great Britain to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea; and

• Sativex® (nabiximols) oral solution , a product approved and marketed in the U.K., Canada and other markets as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis, or MS, who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.

Oncology

• Zepzelca® (lurbinectedin) , a product approved by FDA in June 2020 and launched in the U.S. in July 2020 for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based chemotherapy; i n Canada, Zepzelca was approved in September 2021 for the treatment of adults with Stage III or metastatic SCLC, who have progressed on or after platinum-containing therapy;

• Rylaze™ (recombinant Erwinia asparaginase), a product approved by FDA in June 2021 and launched in the U.S. in July 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia, or ALL, or lymphoblastic lymphoma, or LBL, in adults and pediatric patients who have developed hypersensitivity to E. coli -derived asparaginase;

• Vyxeos® (daunorubicin and cytarabine) liposome for injection , a product approved in the U.S., Canada, Europe and Great Britain (marketed as Vyxeo

Free historical financial statements for Jazz Pharmaceuticals Plc. See how revenue, income, cash flow, and balance sheet financials have changed over 48 quarters since 2012. Compare with JAZZ stock chart to see long term trends.

Data imported from Jazz Pharmaceuticals Plc SEC filings. Check original filings before making any investment decision.